^
    Back
    Association details:
    Biomarker:RNASET2 overexpression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Zolinza (vorinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    BMC Cancer
    Title:

    Systematic analysis of RNASET2 gene as a potential prognostic and immunological biomarker in clear cell renal cell carcinoma

    Published date:
    09/07/2023
    Excerpt:
    Similarly, high expression of RNASET2 in some targeted therapeutic agents increases the sensitivity of patients to the drug, such as vinblastine, linifanib, midostaurin, and vorinostat (Fig. 7, H to K).
    DOI:
    https://doi.org/10.1186/s12885-023-11356-6